Beam Therapeutics Inc [BEAM] stock prices are down -5.56% to $26.32 at the moment. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The BEAM shares have gain 2.21% over the last week, with a monthly amount glided 22.13%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Beam Therapeutics Inc [NASDAQ: BEAM] stock has seen the most recent analyst activity on October 09, 2025, when Jefferies initiated its Buy rating and assigned the stock a price target of $41. Previously, BofA Securities upgraded its rating to Buy on March 28, 2025, and kept the price target unchanged to $42. On March 10, 2025, upgrade upgraded it’s rating to Sector Outperform but maintained its price target of $40 on the stock. Cantor Fitzgerald upgraded its rating to a Overweight. Leerink Partners upgraded its rating to a Outperform and raised its price target to $39 on November 06, 2024. In a note dated July 23, 2024, H.C. Wainwright initiated a Buy rating and provided a target price of $80 on this stock.
The stock price of Beam Therapeutics Inc [BEAM] has been fluctuating between $13.52 and $35.25 over the past year. Currently, Wall Street analysts expect the stock to reach $48 within the next 12 months. Beam Therapeutics Inc [NASDAQ: BEAM] shares were valued at $26.32 at the most recent close of the market. An investor can expect a potential return of 82.37% based on the average BEAM price forecast.
Analyzing the BEAM fundamentals
The Beam Therapeutics Inc [NASDAQ:BEAM] reported sales of 60.27M for trailing twelve months, representing a drop of -28.08%. Gross Profit Margin for this corporation currently stands at 0.04% with Operating Profit Margin at -7.4%, Pretax Profit Margin comes in at -6.61%, and Net Profit Margin reading is -6.61%. To continue investigating profitability, this company’s Return on Assets is posted at -0.29, Equity is -0.43 and Total Capital is -0.37. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.15.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It’s worth pointing out that Beam Therapeutics Inc [NASDAQ:BEAM]’s Current Ratio is 6.75. In addition, the Quick Ratio stands at 6.75 and the Cash Ratio stands at 1.62. Considering the valuation of this stock, the price to sales ratio is 44.18, the price to book ratio is 2.53.
Transactions by insiders
Recent insider trading involved Cavanagh Bethany J, SVP, Finance and Treasurer, that happened on Oct 01 ’25 when 467.0 shares were sold. Chief Legal Officer, Bellon Christine completed a deal on Oct 01 ’25 to sell 373.0 shares. Meanwhile, CEO Evans John M. sold 25000.0 shares on Oct 02 ’25.
